Enanta Pharmaceuticals (ENTA) EBIT Growth (5y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.78% |
| Dec 31, 2025 | 1.76% |
| Sep 30, 2025 | 1.45% |
| Jun 30, 2025 | 3.73% |
| Mar 31, 2025 | -15.61% |
| Dec 31, 2024 | -30.80% |
| Sep 30, 2024 | -46.04% |
| Jun 30, 2024 | -53.21% |
| Mar 31, 2024 | -90.56% |
| Dec 31, 2023 | -26.60% |
| Sep 30, 2023 | -23.74% |
| Jun 30, 2023 | -29.35% |
| Mar 31, 2023 | -34.12% |
| Dec 31, 2022 | -32.52% |
| Sep 30, 2022 | -20.09% |
| Jun 30, 2022 | -19.90% |
| Mar 31, 2022 | -28.92% |
| Dec 31, 2021 | -33.97% |
| Sep 30, 2021 | -61.19% |
| Jun 30, 2021 | -98.84% |
| Mar 31, 2021 | -120.87% |
| Dec 31, 2020 | -18.59% |
| Sep 30, 2020 | -49.16% |
| Jun 30, 2020 | -72.83% |
| Mar 31, 2020 | -17.55% |
| Dec 31, 2019 | -28.77% |
| Sep 30, 2019 | 26.25% |
| Jun 30, 2019 | -35.97% |
| Mar 31, 2019 | 23.95% |
| Dec 31, 2018 | 48.02% |
| Sep 30, 2018 | 56.30% |
| Jun 30, 2018 | 49.30% |
| Mar 31, 2018 | 44.10% |
| Dec 31, 2017 | -8.08% |
| Sep 30, 2017 | 72.46% |
| Jun 30, 2017 | -30.06% |
| Mar 31, 2017 | -18.09% |